急性一氧化碳中毒脑损伤的早期预测指标及亚低温的神经保护作用
该研究纳入2013至2018年277例急性重症一氧化碳中毒患者,按入院当天体温及治疗意愿分为发热组(n=78)、常温组(n=113)和亚低温组(n=86),所有患者均接受高压氧治疗,亚低温组额外接受亚低温治疗。结果显示亚低温治疗改善预后,显著降低脑氧利用率(O2UCc)和神经元特异性烯醇化酶(NSE),上调脑电双频指数(BIS)。6个月时迟发性脑病(DEACMP)发生率在发热组为27%、常温组为23%、亚低温组为8%。G-P评分、BIS指数和NSE与DEACMP发生密切相关,其截断值分别为12.41、52.17和35.20 ng/mL,ROC曲线下敏感度和特异度分别为79.3%、77.6%、79.3%和67.6%、89.5%、88.6%。
要点
- 亚低温组6个月DEACMP发生率为8%,低于发热组的27%和常温组的23%。
- 亚低温治疗可显著降低O2UCc和NSE,并上调BIS指数。
- G-P评分预测DEACMP的截断值为12.41,敏感度79.3%、特异度67.6%。
- BIS指数预测DEACMP的截断值为52.17,敏感度77.6%、特异度89.5%。
- NSE预测DEACMP的截断值为35.20 ng/mL,敏感度79.3%、特异度88.6%。
适用人群与场景
- 2013至2018年本院收治的急性重症一氧化碳中毒患者,共277例。
- 按入院当天体温及治疗意愿分为发热组(n=78)、常温组(n=113)和亚低温组(n=86)。
诊断标准与关键阈值
- G-P评分预测DEACMP的截断值为12.41,ROC曲线敏感度79.3%、特异度67.6%。
- BIS指数预测DEACMP的截断值为52.17,ROC曲线敏感度77.6%、特异度89.5%。
- NSE预测DEACMP的截断值为35.20 ng/mL,ROC曲线敏感度79.3%、特异度88.6%。
处置流程与药物剂量
- 所有患者均接受高压氧治疗。
- 亚低温组在高压氧治疗基础上接受亚低温治疗。
研究设计与关键结果
- 研究纳入277例急性重症一氧化碳中毒患者,分为发热组(n=78)、常温组(n=113)和亚低温组(n=86),所有患者接受高压氧治疗,亚低温组额外接受亚低温治疗。
- 亚低温治疗改善一氧化碳中毒患者预后,显著降低O2UCc和NSE值,上调BIS。
- 6个月时DEACMP发生率:发热组27%、常温组23%、亚低温组8%。
- G-P评分、BIS指数和NSE与DEACMP发生密切相关,截断值分别为12.41、52.17和35.20 ng/mL,ROC曲线敏感度和特异度分别为79.3%、77.6%、79.3%和67.6%、89.5%、88.6%。
证据类型、等级与局限
- 证据类型:临床研究(根据摘要描述为队列研究),样本量277例。
- 临床注册与伦理审批号:QD81571283(青岛大学研究伦理委员会)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 早期亚低温治疗可显著降低一氧化碳中毒后脑损伤严重程度,作者认为可能进一步在临床推广。
- G-P评分、NSE和BIS指数可作为DEACMP发生和发展的预测指标。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Carbon monoxide (CO) poisoning can cause serious neurological sequelae. However, there is neither effective treatment strategy nor reliable indicators to determine the prognosis of patients with CO poisoning. The present study aimed to observe the changes of neurological function score, disease severity score, cerebral oxygen utilization (O2UCc), bispectral (BIS) index and neuron-specific enolase (NSE) concentration, and to elucidate the clinical significance of these potential indicators and the neuroprotective effect of mild hypothermia on brain injury in patients with severe acute CO poisoning.
MATERIALS AND METHODS: A total of 277 patients with acute severe CO poisoning from 2013 to 2018 were enrolled in our hospital. Patients were divided into three groups according to their body temperature on the day of admission and their willingness to treat: a fever group (n = 78), a normal temperature group (NT group, n = 113), and a mild hypothermia group (MH group, n = 86). All patients were given hyperbaric oxygen therapy, while those in the MH group received additional mild hypothermia treatment. The severity of the disease, the neurobehavioral status, the incidence of delayed encephalopathy after acute carbon monoxide poisoning (DEACMP), and other indicators including BIS, O2UCc, NSE were further evaluated in all patients at given time-points.
RESULTS: Mild hypothermia therapy improved the prognosis of patients with CO poisoning, significantly decreased the value of O2UCc and NSE, and up-regulated BIS. The incidence of DEACMP at 6 months was 27% in the fever group, 23% in the NT group, and 8% in the MH group. The values of Glasgow-Pittsburgh coma scale (G-P score), BIS index and NSE were closely related to the occurrence of DEACMP, the cutoff values were 12.41, 52.17 and 35.20 ng/mL, and the sensitivity and specificity were 79.3%, 77.6%, 79.3% and 67.6%, 89.5%, 88.6% in the receiver operating characteristic curve (ROC), respectively.
CONCLUSIONS: Early mild hypothermia treatment could significantly reduce the severity of brain injury after CO poisoning, and might be further popularized in clinic. G-P scores, NSE and BIS index can be regarded as the prediction indicators in the occurrence and development of DEACMP.
CLINICAL TRIAL REGISTRATION: The study protocol was granted from Qingdao University Research Ethics Committee (Clinical trial registry and ethical approval number: QD81571283).
参考来源
- Zhang JJ, Bi WK, Cheng YM, et al. Early predictors of brain injury in patients with acute carbon monoxide poisoning and the neuroprotection of mild hypothermia. Am J Emerg Med. 2022. PMID: 36029667. doi:10.1016/j.ajem.2022.08.016
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。